ArticleThe Journal of pharmacology and experimental therapeutics2024
A Synthetic ERR Agonist Alleviates Metabolic Syndrome.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Pooled it
- Pharmacology of estrogen-related receptors (ERRs) agonists.RSC chemical biology · 2026Review
- Exercise mimetics: molecular mechanisms, biological and therapeutic effects.Molecular biomedicine · 2026Review
- Exercise pills for cardiometabolic health cannot mimic the exercise milieu.Trends in endocrinology and metabolism: TEM · 2026Review
- Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.International journal of biological macromolecules · 2026Article
- Nuclear Receptor-Targeted Therapies: Reprogramming Metabolism with TRβ, ERRα, and LXR Modulators.Biomolecules · 2026Review
- Structural Pharmacology of Estrogen-Related Receptors.ACS pharmacology & translational science · 2026Review
- Hepatic mitochondrial signaling as a systemic hub: inter-organ communication networks in aging and aging-related diseases.Frontiers in cell and developmental biology · 2026Review
- Cold exposure induces the constitutively active thermogenic receptor, GPR3, via ERRα and ERRγ.Molecular metabolism · 2026Article
- Multi-layered transcriptional control of glycogen metabolism coordinates thermogenic remodeling of white adipocytes in male mice.Nature communications · 2025Article
- Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease.American journal of physiology. Renal physiology · 2025Review
- The relationship between metabolic syndrome and environmental endocrine disruptors: A systematic review and meta-analysis.iScience · 2025Article
- Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025Article
- Mitochondrial Quality Control: A New Perspective in Skeletal Muscle Dysfunction of Chronic Obstructive Pulmonary Disease.Aging and disease · 2024Review
- The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB.Molecular pharmacology · 2024Article
- Article
- Estrogen-Related Receptor α: A Key Transcription Factor in the Regulation of Energy Metabolism at an Organismic Level and a Target of the ABA/LANCL Hormone Receptor System.International journal of molecular sciences · 2024Review
- Endometrial expression of ERRβ and ERRγ: prognostic significance and clinical correlations in severe endometriosis.Frontiers in endocrinology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Cyrielle BillonCenter for Clinical Pharmacology, St. Louis College of Pharmacy, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, Missouri (C.B., A.A., B.E.); Department of Pharmacology & Physiology (E.S., A.C., A.A.B., J.K.W.) and Department of Chemistry (J.K.W.), Saint Louis University School of Medicine, St. Louis, Missouri; and University of Florida Genetics Institute, Gainesville, Florida (T.P.B.) cyrielle.billon@uhsp.edu burris.thomas@ufl.edu.
Emmalie SchoepkeCenter for Clinical Pharmacology, St. Louis College of Pharmacy, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, Missouri (C.B., A.A., B.E.); Department of Pharmacology & Physiology (E.S., A.C., A.A.B., J.K.W.) and Department of Chemistry (J.K.W.), Saint Louis University School of Medicine, St. Louis, Missouri; and University of Florida Genetics Institute, Gainesville, Florida (T.P.B.).
Amer AvdagicCenter for Clinical Pharmacology, St. Louis College of Pharmacy, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, Missouri (C.B., A.A., B.E.); Department of Pharmacology & Physiology (E.S., A.C., A.A.B., J.K.W.) and Department of Chemistry (J.K.W.), Saint Louis University School of Medicine, St. Louis, Missouri; and University of Florida Genetics Institute, Gainesville, Florida (T.P.B.).
Arindam ChatterjeeCenter for Clinical Pharmacology, St. Louis College of Pharmacy, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, Missouri (C.B., A.A., B.E.); Department of Pharmacology & Physiology (E.S., A.C., A.A.B., J.K.W.) and Department of Chemistry (J.K.W.), Saint Louis University School of Medicine, St. Louis, Missouri; and University of Florida Genetics Institute, Gainesville, Florida (T.P.B.).
Andrew A ButlerCenter for Clinical Pharmacology, St. Louis College of Pharmacy, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, Missouri (C.B., A.A., B.E.); Department of Pharmacology & Physiology (E.S., A.C., A.A.B., J.K.W.) and Department of Chemistry (J.K.W.), Saint Louis University School of Medicine, St. Louis, Missouri; and University of Florida Genetics Institute, Gainesville, Florida (T.P.B.).
Bahaa ElgendyCenter for Clinical Pharmacology, St. Louis College of Pharmacy, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, Missouri (C.B., A.A., B.E.); Department of Pharmacology & Physiology (E.S., A.C., A.A.B., J.K.W.) and Department of Chemistry (J.K.W.), Saint Louis University School of Medicine, St. Louis, Missouri; and University of Florida Genetics Institute, Gainesville, Florida (T.P.B.).
John K WalkerCenter for Clinical Pharmacology, St. Louis College of Pharmacy, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, Missouri (C.B., A.A., B.E.); Department of Pharmacology & Physiology (E.S., A.C., A.A.B., J.K.W.) and Department of Chemistry (J.K.W.), Saint Louis University School of Medicine, St. Louis, Missouri; and University of Florida Genetics Institute, Gainesville, Florida (T.P.B.).
Thomas P BurrisCenter for Clinical Pharmacology, St. Louis College of Pharmacy, Washington University School of Medicine, University of Health Sciences and Pharmacy, St. Louis, Missouri (C.B., A.A., B.E.); Department of Pharmacology & Physiology (E.S., A.C., A.A.B., J.K.W.) and Department of Chemistry (J.K.W.), Saint Louis University School of Medicine, St. Louis, Missouri; and University of Florida Genetics Institute, Gainesville, Florida (T.P.B.).
Saint Louis University · USUniversity of Florida · US
Funding
Targeting REV-ERB to treat Alzheimer's diseaseRF1AG060769 · NIA · UNIVERSITY OF FLORIDA · PI BURRIS, THOMAS P · 2019 to 2019
$3.7MExercise Mimetics for Dementia and Alzheimer's DiseaseRF1AG077160 · NIA · UNIVERSITY OF FLORIDA · PI BURRIS, THOMAS P, ELGENDY, BAHAA · 2023 to 2023
$2.3MERRgamma Agonists to Treat Muscular DystrophyR01AR069280 · NIAMS · ST. LOUIS COLLEGE OF PHARMACY · PI BURRIS, THOMAS P, WALKER, JOHN K. · 2016 to 2018
$1.7MNIAMS NIH HHS R01 AR069280NIA NIH HHS RF1 AG060769NIA NIH HHS RF1 AG077160
Abstract
Physical exercise induces physiologic adaptations and is effective at reducing the risk of premature death from all causes. Pharmacological exercise mimetics may be effective in the treatment of a range of diseases including obesity and metabolic syndrome. Previously, we described the development of SLU-PP-332, an agonist for the estrogen-related receptor (ERR)
Indexed as
Insulin ResistanceMetabolic SyndromeAnimalsEnergy MetabolismERRalpha Estrogen-Related ReceptorEstrogensMiceObesityReceptors, Cytoplasmic and NuclearERRalpha Estrogen-Related ReceptorEstrogensReceptors, Cytoplasmic and Nuclear
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.